Loading...
•
Mar 31, 2024
Protagonist Q1 2024 Earnings Report
Protagonist reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
Key Takeaways
Protagonist Therapeutics announced a transformational partnership with Takeda to develop and commercialize rusfertide, allowing reinvestment in peptide therapeutics and expansion of efforts to create a new pipeline. Enrollment is complete in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis. The company expects to nominate an oral IL-17 antagonist development candidate by the end of 2024.
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda.
Cash runway extended through Q4 2027.
Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis is now complete.
Expect to nominate a development candidate from oral IL-17 program by end of 2024.
Revenue by Segment
Forward Guidance
The company expects to nominate an oral IL-17 antagonist development candidate this year from their internal discovery efforts, and anticipates results from the Phase 2b ANTHEM study in ulcerative colitis.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...